logo-loader
viewTissue Regenix Group PLC

Tissue Regenix's vascular patch "safe and effective," trial shows

Tissue Regenix has received another strong endorsement for its regenerative tissue technology after a vascular patch was shown to be almost indistinguishable from the patients' own veins.

medical_chart350_50499afc9a436.jpg

 

Tissue Regenix (LON:TRX) has received another strong endorsement for its regenerative tissue technology after a vascular patch was shown to be safe and effective in a two –year trial.

The trial involved 21 patients suffering from severe vascular disease that required surgery to restore the flow of blood.

After two years, post-surgery scans of the patched veins showed that it was difficult or impossible to identify Tissue Regenix’s dCELL vascular patch from the patients' own vein, the results showed.

David Russell, consultant vascular surgeon at Leeds General Infirmary, added that the trial had also shown that the dCELL patches were durable.

He said that even though the trial was relatively small the results showed the patch has an excellent safety profile and was a safe and effective alternative for routine vascular use.

“The most encouraging results are the sonographic findings indicating incorporation of the patch into the patients' own veins and no evidence of patch expansion. These suggest that this patch will be durable with excellent patency rates."

The vascular trial follows independent research by Yale University in June that showed the dCELL process was significantly more effective than a US produced alternative.

The author of that research, Alan Dardik an associate professor of surgery at Yale, said today that the outstanding safety profile of dCELL patches showed they were safe for use in general practice.

Tissue’s dCELL technology involves taking human and animal tissue and “washing” it so that it can be used again to replace worn out or diseased body parts without the need for anti-rejection drugs.

Key to the process is that dCELL leaves the structure of the tissue – or the scaffold – intact, enabling the recipient to re-populate it with their own cells and making it suitable for grafts or replacement parts.

Anthony Odell, Tissue Regenix’s managing director, while the healthcare industry is spending millions developing stem cell treatments its technology can deliver treatments effectively but much more efficiently and potentially at a significantly lower cost. 

As well as vascular patches, Tissue is developing cartilage replacements, ligaments and heart valves using its technology.

The company is also working on  a dialysis graft for patients with kidney disease, which it hopes will mitigate some of the associated risks and reduce the cost of expensive dialysis.

 

Quick facts: Tissue Regenix Group PLC

Price: 0.92 GBX

AIM:TRX
Market: AIM
Market Cap: £10.78 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tissue Regenix increasing throughput in its facility to meet 'exceptional...

Tissue Regenix PLC's (LON:TRX) Gareth Jones caught up with Proactive's Andrew Scott to update on developments in the regenerative medical devices maker's second half. ''The focus is really on increasing throughput in our San Antonia facility in the United States to allow us to meet the demand...

on 19/12/19

2 min read